267 related articles for article (PubMed ID: 22322993)
1. A prognostic gene expression signature in infratentorial ependymoma.
Wani K; Armstrong TS; Vera-Bolanos E; Raghunathan A; Ellison D; Gilbertson R; Vaillant B; Goldman S; Packer RJ; Fouladi M; Pollack I; Mikkelsen T; Prados M; Omuro A; Soffietti R; Ledoux A; Wilson C; Long L; Gilbert MR; Aldape K;
Acta Neuropathol; 2012 May; 123(5):727-38. PubMed ID: 22322993
[TBL] [Abstract][Full Text] [Related]
2. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
3. The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas.
Koos B; Bender S; Witt H; Mertsch S; Felsberg J; Beschorner R; Korshunov A; Riesmeier B; Pfister S; Paulus W; Hasselblatt M
Clin Cancer Res; 2011 Jun; 17(11):3631-7. PubMed ID: 21493867
[TBL] [Abstract][Full Text] [Related]
4. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
Shu C; Wang Q; Yan X; Wang J
Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
[TBL] [Abstract][Full Text] [Related]
6. Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology.
Phi JH; Wang KC; Park SH; Kim IH; Kim IO; Park KD; Ahn HS; Lee JY; Son YJ; Kim SK
J Neurooncol; 2012 Feb; 106(3):619-26. PubMed ID: 21863401
[TBL] [Abstract][Full Text] [Related]
7. Utility of copy number variants in the classification of intracranial ependymoma.
Evenson M; Cai C; Hucthagowder V; McNulty S; Neidich J; Kulkarni S; Dahiya S
Cancer Genet; 2020 Jan; 240():66-72. PubMed ID: 31794935
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of chromosome 1q gain in intracranial ependymomas.
Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
[TBL] [Abstract][Full Text] [Related]
9. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
11. Molecular predictive and prognostic factors in ependymoma.
Benson R; Mallick S; Julka PK; Rath GK
Neurol India; 2016; 64(2):279-86. PubMed ID: 26954807
[TBL] [Abstract][Full Text] [Related]
12. Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma.
Hoffman LM; Donson AM; Nakachi I; Griesinger AM; Birks DK; Amani V; Hemenway MS; Liu AK; Wang M; Hankinson TC; Handler MH; Foreman NK
Acta Neuropathol; 2014 May; 127(5):731-45. PubMed ID: 24240813
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
[TBL] [Abstract][Full Text] [Related]
14. Both location and age predict survival in ependymoma: a SEER study.
McGuire CS; Sainani KL; Fisher PG
Pediatr Blood Cancer; 2009 Jan; 52(1):65-9. PubMed ID: 19006249
[TBL] [Abstract][Full Text] [Related]
15. Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases.
Virág J; Haberler C; Baksa G; Piurkó V; Hegedüs Z; Reiniger L; Bálint K; Chocholous M; Kiss A; Lotz G; Glasz T; Schaff Z; Garami M; Hegedűs B
Pathol Oncol Res; 2017 Apr; 23(2):245-252. PubMed ID: 27395057
[TBL] [Abstract][Full Text] [Related]
16. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
17. Ependymoma.
Reni M; Gatta G; Mazza E; Vecht C
Crit Rev Oncol Hematol; 2007 Jul; 63(1):81-9. PubMed ID: 17482475
[TBL] [Abstract][Full Text] [Related]
18. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
19. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival.
Lukashova-v Zangen I; Kneitz S; Monoranu CM; Rutkowski S; Hinkes B; Vince GH; Huang B; Roggendorf W
Acta Neuropathol; 2007 Mar; 113(3):325-37. PubMed ID: 17265049
[TBL] [Abstract][Full Text] [Related]
20. Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis.
Peyre M; Commo F; Dantas-Barbosa C; Andreiuolo F; Puget S; Lacroix L; Drusch F; Scott V; Varlet P; Mauguen A; Dessen P; Lazar V; Vassal G; Grill J
PLoS One; 2010 Sep; 5(9):e12932. PubMed ID: 20885975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
